Altimmune Inc. (ALT) has a clinical trial catalyst to watch in the coming weeks, which has the potential to impact its stock performance.The company is expected to release 48-week data from its Phase 2b IMPACT trial of Pemvidutide in metabolic dysfunction association steatohepatitis (MASH) before the end of this year. The readout is expected to provide long-term insights into efficacy, fibrosis im...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.